To view enhanced content for this article go to http://www.medengine.com/Redeem/7D47F0604CA496AA.
Anti-diabetes medication regimen adherence is a clinical challenge in elderly patients with type 2 diabetes (T2D) and other comorbidities associated with aging. Glucagon-like peptide-1 receptor agonists (GLP-1RA) therapies such as exenatide once weekly (QW), exenatide twice daily (BID), and liraglutide once daily (QD) are an increasingly used class of drugs with proven efficacy and tolerability. Real-world evidence on adherence to GLP-1RAs in elderly or disabled patients is limited. To further the understanding of this drug class, the current study examined medication adherence in Medicare patients aged ≥65 years with T2D initiating a GLP-1RA.
This retrospective cohort study used medical and pharmacy claims between 2010 and 2013 for Medicare members in a United States health plan diagnosed with T2D who were new initiators of either exenatide QW (n = 537), exenatide BID (n = 923), or liraglutide QD (n = 3,673). Included patients were between the ages of 65 and 89 and were continuously enrolled for 6 months pre- and post-index. Medication adherence was examined during the post-index period using proportion of days covered (PDC) ≥80% and ≥90%.
A significantly higher percentage of patients receiving exenatide QW had a PDC ≥80% (43.2%) versus exenatide BID (39.0%, P < 0.01) and liraglutide QD (35.0%, P < 0.001). The patients receiving exenatide QW were significantly more likely to reach a PDC of ≥90% (37.2%, P < 0.001) than those initiating exenatide BID (20.6%) or liraglutide QD (23.3%).
While results from this retrospective study suggest room for improvement in adherence to GLP-1RAs, medication adherence rates for patients initiating therapy with exenatide QW were higher than patients initiating therapy with exenatide BID or liraglutide QD. Further research is needed to validate these findings in other T2D patient populations.
Funding: AstraZeneca Pharmaceuticals.
Center for disease control and prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2011. http://www.cdc.gov/DIABETES/pubs/factsheet11.htm.
ADA. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-46. ( Epub 2013/03/08).
Centers for disease control and prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United Sates, 2014. Atlanta, GA: U.S. Department of Health and Humana Services; 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.
Sloan FA, Bethel MA, Ruiz D, Jr., Shea AM, Feinglos MN. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med. 2008;168(2):192–9 (discussion 9. Epub 2008/01/30).
Chau D, Edelman SV. Clinical management of diabetes in the elderly. Clin Diabetes. 2001;19(4):4. CrossRef
Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A. 2001;56(1):M5–13 ( Epub 2001/02/24). CrossRef
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429–42 ( Epub 2015/01/15). CrossRefPubMed
Amylin Pharmaceuticals, Inc. Bydureon Package Insert. http://druginserts.com/lib/rx/meds/bydureon-2/ Accessed 29 Aug 2014.
Amylin Pharmaceuticals, Inc. Byetta Package Insert. http://druginserts.com/lib/rx/meds/byetta/page/4/. Accessed 29 Aug 2014.
Novo Nordisk. Victoza Package Insert. http://www.novo-pi.com/victoza.pdf. Accessed 29 Aug 2014.
Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17:8. CrossRef
Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2011;34(1):90–5 ( Epub 2010/10/12). CrossRefPubMed
Johnston SS, Nguyen H, Cappell K, Nelson JK, Chu BC, Kalsekar I. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States. J Med Econ. 2015;18(9):666–77 ( Epub 2015/04/14). CrossRefPubMed
CDC. Distribution of first-listed diagnoses among hospital discharges with diabetes as any-listed diagnosis, adults aged 18 years and older, United States, 2010. 2010 [cited 2015 November 5]. http://www.cdc.gov/diabetes/statistics/hosp/adulttable1.htm.
Leslie RS. Using Arrays to Calculate Medication Utilization. SAS Global Forum Orlando, CA; 2007.
Leslie RS, editor. Using Propensity Scores to Adjust for Treatment Selection Bias. Proceedings of Western Users of SAS Software 2008 Educational Forum and Conference, Universal City, CA; 2008.
Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–39 ( Epub 2012/09/14). PubMed
Wang L, Wei W, Miao R, Xie L, Baser O. Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study. BMJ Open. 2013;3(4) ( Epub 2013/05/02).
Yap AF, Thirumoorthy T, Kwan YH. Systematic review of the barriers affecting medication adherence in older adults. Geriatr Gerontol Int. 2015. ( Epub 2015/10/21).
Centers for Medicare & Medicaid Services. Quality Measures. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/index.html. Accessed 30 Apr 2016.
- Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II